Login    Join free Add to favorites    中文
Home > News > CENTOGENE Launches Two Year Global Parkinson鈥檚 Disease Study
Industry Updates New Products Supplier News Upcoming Events business web
CENTOGENE Launches Two Year Global Parkinson鈥檚 Disease Study
hits:124     Date:05/14/19

One of the largest, most ethnically diverse studies of Parkinson鈥檚 disease to uncover the genetic basis of one of the most common neurodegenerative disorders
Cambridge, MA USA & Rostock, Germany 13 May, 2019 鈥 CENTOGENE today announced the initiation of a 24-month global study to investigate the genetic factors in Parkinson鈥檚 disease, one of the most common neurodegenerative disorders that affects approximately 1 per cent of individuals over the age of 60. The 鈥楻ostock International Parkinson鈥檚 Disease Study鈥 (ROPAD) is being conducted in cooperation with the University of L眉beck and is expected to be the largest and most comprehensive study of its kind concerning Parkinson鈥檚 disease.
The study aims to enroll approximately 10,000 participants worldwide, to provide a study cohort with a broad genetic background that mirrors the global population. The objective of the study is to gain a comprehensive understanding of how many and which genetic mutations in Parkinson鈥檚 disease (PD) associated genes are linked to the development of the disease. CENTOGENE will utilize the CentoCard®, its proprietary, CE-marked dried blood spot collection kit to identify participants with a mutation in the LRRK2, GBA and other PD associated genes.
Patients displaying mutations in PD genes will have the option to undergo further clinical assessment in a supplementary study, 鈥楲RRK2 International Parkinson鈥檚 Disease Project (LIPAD)鈥, conducted at the University of L眉beck with the lead of Professor Christine Klein, where a detailed phenotyping of participants will be performed in order to describe the frequency of all important clinical PD signs and symptoms. Patients enrolled in ROPAD with aLRRK2 mutation may also be offered participation in future clinical studies with study partner Denali Therapeutics, which is developing investigational therapies for the treatment of neurodegenerative and other human diseases.
鈥淐ENTOGENE is committed to bringing hope to patients and their families by shortening the diagnostic odyssey, and we are proud to be working on this important study that may have vast implications for the future diagnosis and treatment of Parkinson鈥檚 disease,鈥 said Dr. Arndt Rolfs, Chief Executive Officer and Founder of CENTOGENE. 鈥淎ll too often clinical studies do not reflect the ethnic diversity of the world, and this study is unique in that we are working across all ethnicities worldwide and crosschecking the effect of environmental components and individual genetics. We are excited about the contribution that CENTOGENE and our partners are making in discovering deeper insights into Parkinson鈥檚 disease genetics.鈥
For more information, please watch the following video interview with CENTOGENE CEO Prof. Arndt Rolfs, MD, at: https://www.centogene.com/clinical-studies/global-patient-testing-programs-hl/rostock-international-parkinsons-disease-study.html
CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients. We are focused on bringing rationality to treatment decisions and accelerating the development of new orphan drugs by using our knowledge of the global rare disease market, including our epidemiological and clinical heterogeneity, and our innovative biomarkers.
As one of the largest rare disease companies worldwide, CENTOGENE is dedicated to transforming the science of genetic information into solutions and creating hope for patients with rare diseases and their families. www.centogene.com
Ross Bethell
Director, Corporate Communications
Related News>> more
Copyright(C) 2006-2019 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙